Philip Morris International (PMI) this week submitted its iQOS technology for approval as a reduced-risk product by the U.S. Food and Drug Administration (FDA), a strategy which if successful would provide a tremendous boost to the credibility of heat-not-burn and perhaps pave the way for PMI’s partner Altria to dominate that market in the United States. ...
Sign up to access to our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.